New HER-Vaxx Cancer Vaccine Phase Ib trial data to be presented
at the American Society of Clinical Oncology 2019 Annual Meeting

_____

SYDNEY, Australia, 29 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced updated data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine will be presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019.

The abstract (number 4030) will be presented by Dr Yee Chao, Director of the Department of Oncology at the Veterans General Hospital in Taipei, Taiwan and a lead investigator in the Phase 1b study.

Dr Chao's presentation will be featured at the ASCO Gastrointestinal (Noncolorectal) Cancer Session on Monday 3 June between 8:00am and 11:00am.

The Phase 1b HER-Vaxx study which completed enrolment in 2018 met all its primary endpoints. The study is ongoing with patients continuing to receive HER-Vaxx every 3 months to maintain high levels of cancer targeting antibodies. A Phase 2 study was initiated in March 2019.

The presentation is entitled: 'A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.'

The ASCO annual meeting attracts more than 40,000 cancer specialists and is one of the largest educational and scientific events in the oncology community where the latest research and clinical results are highlighted.

Imugene Managing Director and Chief Executive Officer Leslie Chong said, "There is continued interest in the positive data from our Phase Ib trial which clearly supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer."

Imugene's HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies and now in Phase I studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

The full presentationon will be available on the Imugene website on the day of the presentation.

For further information please contact:
Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body's immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.